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Abstract
Background: Melanoma phenotype and the dynamics underlying its progression are
determined by a complex interplay between different types of regulatory molecules.
In particular, transcription factors (TFs), microRNAs (miRNAs), and long non-coding
RNAs (lncRNAs) interact in layers that coalesce into large molecular interaction
networks. Our goal here is to study molecules associated with the cross-talk between
various network layers, and their impact on tumor progression.
Results: To elucidate their contribution to disease, we developed an integrative
computational pipeline to construct and analyze a melanoma network focusing on
lncRNAs, their miRNA and protein targets, miRNA target genes, and TFs regulating
miRNAs. In the network, we identified three-node regulatory loops each composed
of lncRNA, miRNA, and TF. To prioritize these motifs for their role in melanoma
progression, we integrated patient-derived RNAseq dataset from TCGA (SKCM)
melanoma cohort, using a weighted multi-objective function. We investigated the
expression profile of the top-ranked motifs and used them to classify patients into
metastatic and non-metastatic phenotypes.
Conclusions: The results of this study showed that network motif UCA1/AKT1/hsa-
miR-125b-1 has the highest prediction accuracy (ACC = 0.88) for discriminating
metastatic and non-metastatic melanoma phenotypes. The observation is also
confirmed by the progression-free survival analysis where the patient group
characterized by the metastatic-type expression profile of the motif suffers a
significant reduction in survival. The finding suggests a prognostic value of network
motifs for the classification and treatment of melanoma.
Keywords: Melanoma, Systems biology, RNA motif, LncRNA, MiRNA, Transcription
factor, Network approach, Data integration
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Background
Melanoma is the most severe form of skin cancer. The incidence of melanoma has
risen globally with approximately 96,480 new cases to be diagnosed with almost 7230
estimated deaths in 2019 only in the USA (https://www.cancer.org/cancer/melanoma-
skin-cancer/about/key-statistics.html#references). It arises from melanocytes, the
pigment-producing cells in the basal layer of the epidermis. The progression of normal
melanocytes to metastatic melanoma involves a series of histopathological changes,
from radial growth to vertical growth followed by metastatic spread to distant sites [1].
Recent advancements in tools and technologies have generated heterogeneous multi-
omics data, providing an opportunity to study and understand the concerted aberra-
tions underlying tumor phenotypes [2]. Tumor phenotypes that involve extensive inter-
actions across cell types, at the cellular and tissue levels are particularly suited for
network-based approaches. In our previous work, we have discussed several types of
complex disease networks comprising both the protein-coding and the non-protein-
coding portions of the genome, along with circulatory components (proteins, metabo-
lites, etc.) to assess the risk of developing a metastatic phenotype [3]. Based on this
work, our goal here is to study the interplay between molecules in regulatory networks
and its implications in tumor progression. Integration of molecules across regulatory
layers composed of microRNAs (miRNAs), long non-coding RNAs (lncRNAs), mRNAs,
and transcription factors (TFs) provides insights into molecular mechanisms that can-
not be understood by analyzing individual disease factors. Moreover, it is also recog-
nized that communication between regulatory layers is a highly non-linear process, and
that can be studied using network-based approaches [4].
Over the last decade, several studies demonstrated the role of miRNAs in the context
of tumor growth, invasion, and angiogenesis through translational repression or deg-
radation of their respective target mRNAs [5–7]. Similar to miRNAs, lncRNAs are ex-
quisitely regulated, highly diverse in function, and play an important role in
tumorigenesis [8]. However, due to diverse modifications at the levels of transcription,
post-transcriptional processing, and chromatin remodeling; the mechanistic impact of
most lncRNAs remain unknown [9]. One class of lncRNAs acts as sponges through the
presentation of excess miRNA binding sites that sequester miRNAs away from mRNAs,
thereby inducing de-repression of gene expression. Some lncRNAs function as decoy
molecules that regulate gene expression by competitive inhibition of protein function
through sequestration [10–12]. Even though the importance of their role is well estab-
lished in the context of cancer, only a few experimentally supported lncRNA-protein
and lncRNA-miRNA associations have been reported. In the present work, we first ex-
amined lncRNAs that are associated with tumor progression from non-metastatic to
metastatic melanoma phenotypes by regulating molecules from different regulatory
layers. Further, we constructed a network by incorporating melanoma-associated
lncRNAs, their potential binding partners (miRNAs and proteins), TFs regulating miR-
NAs, and melanoma-associated genes. We analyzed the integrated network to find mo-
lecular signatures associated with the cross-talk between various network layers in the
form of regulatory loops (lncRNA-miRNA-TF).
Furthermore, we integrated patient-derived TCGA skin cutaneous melanoma
(SKCM) RNAseq dataset, mean-normalized (per gene) across all TCGA cohorts onto
the regulatory network. We identified top-ranked motifs based on topological and non-
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topological properties of their constituting nodes. More specifically, we used the top-
ology parameters degree, betweenness centrality, closeness centrality, and clustering co-
efficient. The degree parameter corresponds to the number of edges attached to a
node. A node with a high degree is often called a ‘hub’ and is known to play a central
role in organizing the network. Hub nodes are more likely to be essential than non-
hubs because they have more interaction partners and thus have a higher chance to en-
gage in an essential interaction [13]. The betweenness centrality parameter indicates
the influence of a node on the control of information flow in the network. Nodes with
high betweenness centrality are also called ‘gatekeepers’ and control the communica-
tion between different network components [14]. The closeness centrality parameter
can be interpreted as a measure of how quickly a node can interact with other nodes of
the network. Such central nodes are important because they are easy to reach and be-
long to the core of the network where the majority of nodes interact quickly [15]. The
clustering coefficient parameter shows the degree of clustering of a typical node’s
neighborhood. This property describes the local network structure surrounding a node.
In integrated networks, clustering is considerably and significantly higher than expected
in random networks [16]. Among the non-topological properties, we have used disease
pathway association and context-specific expression profiles of the nodes.
From the top-ranked motifs, we identify unique signatures that can be used to iden-
tify patients with a metastatic melanoma phenotype. Investigation of downstream mole-
cules regulated by these signatures helps in deciphering key processes responsible for
the development of metastatic phenotype. We suggest that the identified lncRNA-
associated regulatory network motifs have a prognostic value to assess the likelihood of
metastatic progression.
Results
The regulatory networks were obtained from a multi-step analysis including the identi-
fication of lncRNAs in melanoma, their potential binding partners (miRNAs and pro-
teins), melanoma-associated genes, and TFs regulating miRNAs. The developed
pipeline is summarized in Fig. 1. For miRNAs, experimentally validated information re-
lated to their target genes is available in several databases. However, for lncRNAs, the
information about their interaction partners is largely missing. In our study, we identi-
fied miRNAs that can potentially be sponged by melanoma-associated lncRNAs. For
that, we built an in-house Python script (Additional file 1: Data S1) to retrieve the nu-
cleotide sequences of melanoma-associated lncRNAs from the NCBI database. We then
used the RNAhybrid tool to identify energetically favorable hybridization sites for miR-
NAs in the target sequence based on dynamic programming. For each of the identified
174 complementary pairs (Additional file 1: Table S1A), we obtained the minimum free
energy (mfe) of hybridization and the position of the binding site on the lncRNA. For
visualization, hybridization maps of the putative miRNA binding sites on the lncRNAs
were generated (Additional file 1: Figures S1-S17). Many miRNAs were found to have
either partial or completely overlapping binding sites on the same lncRNA, which may
result in binding competition among miRNAs. To identify the miRNA with the highest
probability of binding, we assembled miRNA binding clusters from binding sites lo-
cated in close proximity to each other (distance ≤25 nt) as defined by Saetrom et al.
[17]. In each cluster, the miRNA with the most negative mfe of hybridization is selected
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Fig. 1 An integrative network-driven pipeline for discriminating non-metastatic and metastatic melanoma
phenotypes based on lncRNA-associated regulatory network motifs. a Intermolecular interaction data
between regulatory molecules (lncRNA, miRNA, and gene/TF) are extracted from public databases, literature,
and predicted using existing tools (RNAhybrid, RPISeq). b Interactions are merged together to generate an
integrated network. Topological properties of the network are investigated with the Network Analyzer
plugin in Cytoscape. Non-topological properties, including disease pathway association retrieved from KEGG
database and expression profiles of the nodes obtained from a melanoma-specific patient dataset from
UCSC Xena. c Important regulatory loops comprising of lncRNA-miRNA-TF are predicted with the help of
NetDS Cytoscape plugin. d Network motifs are prioritized using a multi-objective function by providing
user-defined weights in an iterative manner. e Calculation of motifs prediction accuracy and
survival analysis
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and accepted into a lncRNA-miRNA interaction network (Additional file 1: Figure
S18). Next, we searched miRTarBase for experimentally validated targets (mRNAs) of
melanoma-associated miRNAs in Homo sapiens at the post-transcriptional level and se-
lected only functional miRNA-target interactions (Additional file 1: Table S1B). The
protein products of many of these target genes act as TFs to regulate miRNA precursor
gene expression. Here, this translated into a total of 247 TF-miRNA interactions from
the TransmiR database as shown in Additional file 1: Table S1C and Figure S19. Fur-
thermore, to connect TFs with the lncRNA layer, we first imported protein sequences
from the NCBI Protein database using Python script (Additional file 1: Data S1) and
calculated interaction probabilities with the melanoma-associated lncRNAs from
Table 1. From the prediction results, we obtained a total of 129 pairs of lncRNAs and
TFs which are very likely to interact (Additional file 1: Table S1D). To further identify
associations among TFs present in the network, we searched the literature and obtained
a total of 22 TF-TF interactions which are reported in Additional file 1: Table S1E. Fi-
nally, we constructed an integrated regulatory network of melanoma (in Fig. 2) which
includes (i) lncRNA-miRNA; (ii) miRNA-target gene; (iii) TF-miRNA; (iv) lncRNA-TF;
and (v) TF-TF interactions. The main purpose of this integrated network is to deter-
mine the cross-talk among all the regulatory layers that give rise to the disease
phenotype.
Identification of regulatory network motifs composed of lncRNA, miRNA, and TF
For the identification of regulatory network motifs, the integrated network was trans-
formed into a format suitable for the NetDS Cytoscape plugin. Restricting the loop size
to three nodes, we obtained 4050 regulatory loops from the integrated network. From
this large set, we selected those loops (n = 600) that uniquely possess all three types of
regulatory components (miRNA, lncRNA, and TF). Further, we used various network
topological and non-topological parameters to rank regulatory loops (Additional file 1:
Table S1F). The parameters are described in the “Background” section.
Weighting of parameters for prioritization of motifs
To select the most representative and relevant motifs for the metastatic and non-
metastatic group, we prioritized the sets of motifs using a multi-objective function. The
function integrates both topological and non-topological parameters, and ranks the mo-
tifs. We assigned different weights to the nodes according to Eq. (1) discussed below.













þw3 jðRNAEXPÞi þ w4 jðmiRNAEXPÞi þ w5 jðT FEXPÞi
ð1Þ
Where Sij is the ranking score of each motif in different weighting scenarios
(i = 1 … n: motif and j = 1 … m: scenario), and w1j-5j are weighting factors govern-
ing the importance of the properties which are: DP, motif’s average node disease
pathway association i.e. number of motif nodes participating in KEGG pathways
(hsa05200-Pathways in cancer, hsa05206–MicroRNAs in cancer, and hsa05202-
Transcriptional misregulation in cancer); BC, motif’s average node betweenness
centrality; CC, motif’s average node clustering coefficient; CnC, motif’s average
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node closeness centrality; Deg, motif’s average node degree; and lncRNAEXP, miR-
NAEXP, TFEXP are metastatic and non-metastatic patient-derived expression profile
(pan-cancer normalized log2) of node0, node1, node2 from each motif (i) respect-
ively. Weighting scenarios for motif prioritization are given in Additional file 1:
Table S2. In the first five scenarios (set 1 and 2), we considered only non-
topological parameters while in later scenarios (set 3, 4 and 5) we included combi-
nations of all eligible parameters for motifs ranking. For each weighting scenario,
we calculated the result of the objective function for each network motif, and then
selected the top ten motifs from each of the 13 weighting scenarios implemented
in the multi-objective function. Finally, duplicate motifs were removed, resulting in
20 prioritized motifs in non-metastatic and 25 prioritized motifs in metastatic mel-
anoma (Additional file 1: Table S1G).
Table 1 Experimentally validated melanoma-associated lncRNAs in Homo sapiens
Melanoma-associated lncRNAs
LncRNA name NCBI accession Alias Dysfunction
Type
Function PMID














GAS5 NR_002578 NCRNA00030; SNHG2 Regulation Cell migration and
invasion
26846479











LINC00032 NR_026679 C9orf14; NCRNA00032 Mutation Nevus development 17099875
LINC00673 NR_036488 HILNC75; LUCAIR1; SLNCR1;
HI-LNC75; SLNCR; ERRLR01
Expression Invasion 27210747
MALAT1 NR_002847 NEAT2; LINC00047;
NCRNA00047; HCN;
PRO2853
Expression Cell migration 24892958
MGC16025 NR_026664.1 LOC85009; MELOE Expression Immunosurveillance 27486971
MIR31HG NR_027054 LncHIFCAR; hsa-lnc-31 Regulation Transcriptional
regulator
25908244
PTENP1 NR_023917.1 PTEN-rs; PTH2; PTENpg1;
PTEN2; psiPTEN
Regulation Tumor suppressor 21833010
SAMMSON NR_110000 LINC01212 Regulation Cell growth and
survival
27008969





SPRY4-IT1 NR_131221 SPRIGHTLY Regulation Cell invasion &
proliferation
25344859





UCA1 NR_015379 LINC00178; UCAT1;
CUDR; onco-lncRNA-36;
NCRNA00178
Expression Cell migration 24892958
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Regulatory connections between nodes of the prioritized motifs
We compared prioritized sets of motifs associated with metastatic and non-metastatic
melanoma. We obtained three regulatory network motifs in the metastatic melanoma
phenotype whose constituting nodes did not appear in any of the prioritized motifs in
case of patients with non-metastatic melanoma.
The first motif features the lncRNA small nucleolar RNA host gene 5 (SNHG5),
which binds to the protein cyclin-dependent kinase 4 (CDK4). We predicted this inter-
action using the tool RPISeq, which assigns a high likelihood of binding to this inter-
action pair (0.979 and 0.75 through SVM and RF classifier, respectively). The
expression profile of SNHG5 and its role in facilitating CDK4 expression in tumorigen-
esis have been defined in the literature [18]. We also found that SNHG5 contains a
complementary binding site for the miRNA hsa-let-7a-3p. This implies the sequestra-
tion of the miRNA from its target, suggesting that SNHG5 can act as a sponge for the
miRNA hsa-let-7a-3p. Next, we obtained a reverse correlation between the expression
of miRNA hsa-let-7a-3p and its target protein CDK4, suggesting that CDK4 could also
be down-regulated by hsa-let-7a-3p. This interaction was experimentally detected by
Kim et al. [19].
The second motif contains the GATA-binding protein 3 (GATA3), the lncRNA
SNHG5, and miRNA hsa-let-7a-3p. The interaction probabilities obtained for GATA3
and SNHG5 are 0.75 (RF) and 0.954 (SVM), respectively. This implies that SNHG5 by
binding and sequestering can alter the function of GATA3. It is also apparent that
SNHG5 has a sponge effect on miRNA hsa-let-7a-3p as discussed earlier. Further,
Fig. 2 Interaction network of lncRNA, miRNA, and TF in melanoma. Each rectangular node (peach color)
indicates lncRNAs which acting as miRNA sponges and affect proteins. Each octagon node (yellow color)
indicates experimentally validated TFs which regulate (activation or repression) miRNAs. The network shows
miRNAs (rectangular node, cyan color) that negatively regulates the expression of target genes, and it also
includes interactions between TFs. The network comprises 174 nodes, including melanoma-associated
lncRNAs (17), miRNAs (132), and TFs (25). Network edges (total 655) are colored by the type of interaction
between the nodes which are as follows: T bar-shaped edge for functional MTI (light blue color), repression
(dark green color), down-regulation (black color); broadhead shaped-arrow for activation (purple color), up-
regulation (black color), regulation (purple color); and an undirected edge for binding (fluorescent
green color)
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miRNA hsa-let-7a-3p is predicted to bind to the target site on the GATA3 transcript
and negatively regulate the expression of GATA3 protein. This interaction was exam-
ined in breast cancer through HITS-CLIP performed by Pillai et al. [20].
In the third motif, comparatively a high-probability pairing was obtained between
the lncRNA urothelial cancer-associated 1 (UCA1) and the protein AKT Serine/
Threonine Kinase 1 (AKT1), which is higher than first and second motif (0.973
and 0.9 through SVM and RF classifier, respectively). The expression of UCA1 is
positively correlated with AKT1 activity and this interaction was experimentally
confirmed by Yang et al. [21]. Further, UCA1 down-regulates miRNA hsa-miR-
125b-1 by sequestration, serving as a sponge with high-degree complementarity at
the binding sites. In turn, AKT1 negatively regulates miRNA hsa-miR-125b-1 at
the transcriptional level [22].
Validation of the prioritized motifs in predicting non-metastatic and metastatic
phenotype
As the obtained three motifs were prioritized in the metastatic melanoma phenotype,
we hypothesized that these motif signatures can be used to distinguish metastatic mel-
anoma patients from others. To validate our hypothesis, we investigated the expression
profile of lncRNA, miRNA, and TF using RNAseq data from 477 TCGA (SKCM) sam-
ples available at https://gdc.xenahubs.net version 08-07-2019 [23]. Out of 477 patient
samples, we found 408 samples with expression profiles of the nodes constituting all
the identified regulatory network motifs.
First, we grouped patient samples (total 408) into metastatic and non-metastatic
phenotype based on their clinical pathologic_stages. For that, we classified tumor
samples belonging to stages 0, I, IA, IB, II, IIA, IIB, IIC as non-metastatic; and
stages III, IIIA, IIIB, IIIC, IV as metastatic [24]. The assignment of melanoma
tumor stage generally requires a large number of clinical parameters (such as
serum LDH level, the mitotic rate per mm2, ulceration status, level of invasion,
metastatic volume, number of nodal metastasis, tumor thickness, etc.) and is highly
critical to decide therapy regime. To evaluate whether the three unique regulatory
network motifs identified in the metastatic melanoma phenotype can help to dis-
tinguish metastatic patients, we classified patients based on the motifs’ expression
patterns (up-regulation/down-regulation of nodes) (Table 2). For each node, we ob-
tained the canonical expression pattern (up-regulation or down-regulation) in
metastatic melanoma from literature. This allowed us to define the motifs’ signa-
ture patterns in metastatic samples. For each sample, we then calculated the fold
change of each motif node with respect to its overall-mean expression in all 408
samples (Additional file 1: Table S3). The 408 samples were then classified as
metastatic if the respective genes’ up−/down-regulation profile matched the motif
in question’s signature pattern, or as non-metastatic otherwise (Additional file 1:
Table S1H-J). With this classification scheme, the highest prediction accuracy was
reached by motif 3 (ACC = 0.88), followed by motif 1 (ACC = 0.81) and motif 2
(ACC = 0.60) as represented in Fig. 3. Overall, the results indicate that motif 3
(UCA1/AKT1/hsa-miR-125b-1) has the best predictive power in distinguishing
metastatic and non-metastatic phenotypes of SKCM tumor samples.
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Furthermore, we used data from the previous dataset and performed survival analysis
considering progression-free survival time using GraphPad Prism 7.05 [25]. For this, we
stratified the cohort into three subgroups; 1) samples conforming to the signature ex-
pression patterns; 2) samples conforming to the anti-signature expression patterns (i.e.
expression pattern opposite to the signature in Table 2); and 3) samples that do not
conform to either signature or anti-signature patterns. The log-rank (Mantel-Cox) test
was used to compare the survival distributions. We observed a significant correlation
between the three subgroups regarding motif signatures and progression-free survival
time (Fig. 4). The results obtained from the overall comparison indicated that all the
three motifs can distinguish metastatic melanoma patients with a significant time dif-
ference (at P-value< 0.0001). We also observed that motif 3 showed the largest survival
time difference (1889 days) between Signature and Anti-Signature, followed by motif 1
(675 days) and motif 2 (255 days), which is in accordance with our earlier findings in
the ROC analysis. Further, motif 3 was best able to differentiate the three patient sub-
groups in a pairwise fashion (Signature vs Anti-Signature, P-value = 0.0019 and Signa-
ture vs Others, P-value< 0.0001; in Additional file 1: Table S1K). Altogether, our
analysis suggested that the expression profiles of nodes in motif 3 (UCA1/AKT1/hsa-
miR-125b-1) can be used for quick assignment of metastatic or non-metastatic pheno-
types to melanoma patients.
Discussion
In this article, we study the interplay of molecules (lncRNAs, miRNAs, and TFs) and
their integration across regulatory layers of networks to decipher tumor phenotypes
and the underlying mechanisms of melanoma metastasis. A network-driven pipeline is
developed which combines heterogeneous genomic datasets related to lncRNAs in mel-
anoma, their potential binding partners (lncRNA-miRNA; lncRNA-TF), melanoma-
associated genes (miRNA-target gene), TFs regulating miRNAs (TF-miRNA), and TF-
TF interactions to determine the cross-talk between various network layers, and their
impact on tumor progression and disease phenotype. The study exclusively identified
three lncRNA-associated regulatory network motifs in metastatic patients based on the
calculation and prioritization of topological and non-topological properties. The ap-
proach was evaluated by investigating the expression profile of the motifs and used
them to classify patients into metastatic and non-metastatic phenotypes. The prediction
Table 2 The expression pattern (up-regulation or down-regulation) of motif nodes in Signature
and Anti-Signature
Variable Signature Anti-Signature
Motif 1 CDK4 (UP) CDK4 (DOWN)
SNHG5 (UP) SNHG5 (DOWN)
hsa-let-7a-3p (DOWN) hsa-let-7a-3p (UP)
Motif 2 GATA3 (DOWN) GATA3 (UP)
SNHG5 (UP) SNHG5 (DOWN)
hsa-let-7a-3p (DOWN) hsa-let-7a-3p (UP)
Motif 3 AKT1 (UP) AKT1 (DOWN)
UCA1 (UP) UCA1 (DOWN)
hsa-miR-125b-1 (DOWN) hsa-miR-125b-1 (UP)
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accuracy is calculated for each motif through ROC analysis. Subsequently, the method
was applied to study three subgroups of patients (Signature, Anti-Signature, and
Others) and performed a survival analysis considering progression-free survival time.
The results suggested a prognostic value of motif 3 (UCA1/AKT1/hsa-miR-125b-1) for
discriminating metastatic and non-metastatic melanoma phenotypes with a high pre-
diction accuracy (ACC = 0.88). It is also confirmed from the observation that the
Fig. 3 The ROC space of the three motif signature-based classifiers for their ability to discriminate
metastatic from non-metastatic melanoma samples. The graph shows the superiority of motif 3 in both
sensitivity and specificity. The contingency tables are given below the motifs (True positives TP, True
negatives TN, False positives FP, and False negatives FN), followed by additional performance metrics
(Precision PPV, F1 measure, and Accuracy ACC) for the three classifiers
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expression profile of motif 3 clearly distinguishes patients with metastatic melanoma
phenotype by the lowest mean survival time of 1429 days (at P-value< 0.0001).
Further, to identify the role of the factors in motifs with good predictive power
(CDK4/SNHG5/hsa-let-7a-3p and UCA1/AKT1/hsa-miR-125b-1) in the regulation of
various metastatic tumors, we used Target Mine web server [26] and selected BH
method (Benjamini-Hochberg) for P-value adjustment. For miRNA functional associ-
ation with tumors, we used TAM 2.0 [27] to compare the queries (hsa-let-7a-3p, hsa-
miR-125b-1) with the reference miRNA sets and inferred their disease associations.
The results are plotted in a doughnut chart and a bar graph (Fig. 5). From the func-
tional analysis, we identified pathways in which the constituents of the identified motifs
Fig. 4 Kaplan–Meier plots for progression-free survival probability of patient subgroups (Signature, Anti-
Signature, and Others). This is based on the expression pattern of motif-constituting nodes as defined in
Table 2. Patients that do not follow either Signature or Anti-Signature expression patterns are added in
Others group. For each group, the number of patients (N) and mean progression-free survival time (MS) in
days is provided. The log-rank test was used to assess differences in survival time between all three
patient subgroups
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participate. The obtained top 20 significant pathways are cancer-associated, especially
the ‘breast cancer’ and ‘chronic myeloid leukemia’ pathways are found to be enriched
with most of the regulatory molecules of the motifs. This indicates the possibility that
the screened motifs are also associated with increased risk for developing metastatic
breast cancer and chronic myeloid leukemia. Furthermore, UCA1 and hsa-miR-125b-1
participation were found in 90% of cancer pathways which might suggests that they
play a role not only in melanoma progression but also in other metastatic tumors.
There are some limitations to our approach. First, regarding the detailed annotations
of the lncRNAs, miRNAs, TFs, and their molecular associations; we observed a poor
overlap in the results derived from the different databases and tools. This is probably
due to different data resources or algorithms used to predict these interactions. Second,
our major focus in this study is on lncRNAs and their interacting miRNA, and TF part-
ners. However, several other relevant interactions can take place in different contexts
and may influence the outcome. Hence, a comprehensive view of interactions between
lncRNAs and miRNAs or TFs is still required. Third, in cases where the direction of
regulation (activation/repression) between biomolecules is not reported in the litera-
ture, we have taken as ‘0’ such as lncRNA-miRNA interactions and few lncRNA-TF in-
teractions. So, here the experimental observations’ confirming the nature of their
association is missing. Lastly, the expression profile of motifs investigated from RNAseq
data are limited by false positives and false negatives. To overcome this, we applied adj.
P-value< 0.05 for differential screening to control the FP and FN errors.
Conclusions
The study considers melanoma as an integrated system of regulatory molecules rather
than an outcome of isolated molecular events. Our integrated pipeline applies network-
based approaches to identify key regulatory components (lncRNA, miRNA, and TF) of
the network which enabled a deeper investigation into tumor initiation and progres-
sion. Generalizing this pipeline to other datasets would significantly help in the
Fig. 5 Functional pathway analysis of the constituting nodes of motif 1 and 3 (hsa-miR-125b-1, hsa-let-7a-
3p, SNHG5, UCA1, AKT1, and CDK4) showing the involvement of each node over categories of cancer
pathways in a doughnut chart. The bar graph shows the top 20 significant cancer pathways sorted by P-
value< 0.05 and Z-score > 1.65. The length of the bar represents the significance of that specific pathway
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identification of phenotype-based predictive factors for other disease models. The result
of the present study reveals multi-level interactions between regulatory layers of a mel-
anoma network can be accessed at https://vcells.net/miRNAs-and-lncRNAs-in-melan-
oma/. We have uncovered a potential role for the regulatory network motif UCA1/
AKT1/hsa-miR-125b-1 in melanoma. There is an 88% chance that the expression pro-
file of the motif will correctly distinguish a patient phenotype as non-metastatic or
metastatic melanoma. The result of survival analysis also indicates that the motif has a
good discriminating ability. The findings provide more insights into a systems level un-
derstanding of melanoma progression that comes through the cross-talk between
lncRNA, TF, and miRNA regulatory layers.
Methods
We used computational strategies that combine heterogeneous genomic data to identify
potential coding (TFs) and non-coding (lncRNAs and miRNAs) genes associated with
the biogenesis, development, and differentiation of melanoma cells. Figure 1 provides a
schematic representation of the developed pipeline.
Data collection
We obtained experimentally validated melanoma-associated lncRNAs (in Homo sapi-
ens) from databases such as LncRNADisease [28], Lnc2Cancer [29], and EVlncRNAs
[30], and manually curated them for their functions and associated aliases (in Table 1).
Similarly, we derived experimentally validated melanoma-associated miRNAs (in Homo
sapiens) from databases MiR2Disease [31] and miRBase [32]. Experimentally validated
melanoma-associated gene targets of mature miRNAs were collected from miRTarBase
[33]. Further, FASTA sequences of lncRNAs and proteins were retrieved from NCBI
(https://www.ncbi.nlm.nih.gov) in batch fashion using a Python script.
Prediction of miRNAs and proteins that interacts with lncRNAs
Sequence complementarity between lncRNAs and miRNAs was assessed using RNAhy-
brid [34]. The parameters selected for analysis included an upper energy threshold of −
15 kcal/ mole and a restriction to the top 25 human interactors per lncRNA. The P-value
and minimum free energy (mfe) of hybridization were calculated for hybrid structures.
The regulatory direction of binding interactions between lncRNA and miRNA is taken as
‘0’. Since miRNA suppresses target genes, all the regulatory directions were represented as
inhibitory ‘-1’. Subsequently, we investigated the proteins which are associated with mel-
anoma and checked their interactions with lncRNAs from Table 1 using the RNA-Protein
interaction prediction (RPISeq) tool [35]. The tool provides sequence-based predictions
based on Support Vector Machine (SVM) and Random Forest (RF) classifiers trained on
RPI2241 and RPI369, datasets of RNA-protein interactions. We set a probability value >
0.5 for positive interactions, and selected threshold values by taking the median predicted
values of the positive interactions for both classifiers (i.e. SVM ≥ 0.95 and RF ≥ 0.75). We
also searched for the NPInter 3.0 database for registered lncRNA-TF interactions [36].
Regulatory direction from lncRNA to TF was manually searched from literature either as
activation ‘+1’ or repression ‘-1’. For those cases where the appropriate regulatory role of
lncRNA on TF is missing in the scientific literature, we considered the direction of
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interaction as binding ‘0’. In addition, we collected transcriptional regulatory information
between miRNAs and melanoma-associated proteins which act as TFs from the TransmiR
database [37]. In this case, the regulatory direction was defined based on the ‘Action Type’
parameter from the TransmiR database. We considered activation and regulation as ‘+1’,
while repression is encoded by ‘-1’. Lastly, we derived TF-TF interactions using the Biso-
genet Cytoscape plugin [38]. The regulatory direction between TF-TF was manually ob-
tained from the published literature.
Network construction and analysis
The regulatory relationships were constructed and visualized using Cytoscape 3.7.0
(https://cytoscape.org/) [39]. Various topological properties including centrality param-
eters (degree, closeness centrality, betweenness centrality, and clustering coefficient)
were calculated for each node using the Network Analyzer plugin in Cytoscape [40].
Motif finding and survival analysis
Regulatory network motifs were identified in the integrated network using the NetDS
Cytoscape plugin [41]. To identify the most relevant motifs for the non-metastatic and
metastatic melanoma phenotypes, we followed a method proposed in Khan et al. in 2017
[42]. The method requires the (i) calculation of topological properties of the nodes consti-
tuting a motif, (ii) motif-disease pathway associations, (iii) assignment of a differential ex-
pression value for a motif based on the change in expression values of the constituent
nodes, and (iv) using a weighted multi-objective function as shown in Eq. (1) to rank im-
portant motifs. More details of the pseudo code to reproduce the result are given in Add-
itional file 1: Data S2. To identify key molecular signatures from the top-ranked motifs,
we first divided patient samples into two groups (i.e. metastatic and non-metastatic mel-
anoma phenotypes) based on their respective clinical stages. Further, we analyzed the ex-
pression profile of nodes associated with regulatory network motifs (i.e. up-regulation or
down-regulation from their overall mean expression value calculated using all the melan-
oma patient samples). Patients, where the nodes expression profile (i.e. up-regulation or
down-regulation) matches to the signature patterns, are reclassified as metastatic patients,
whilst others are assigned to non-metastatic group. This reclassification of patients were
compared to the melanoma phenotype based on the clinical pathologic_stages to calculate
the prediction accuracy of motifs. Analysis of data was performed using MedCalc Statis-
tical Software v14.8 [43]. Later, the top-ranked motifs are analyzed for progression-free
survival probability using Kaplan-Meier survival analysis.
Web interface for visualizing and analyzing the network
To facilitate exploration of the reconstructed network and the analyzed data for inter-
ested parties, we uploaded them to the web platform for visualization of biochemical
networks vCells https://vcells.net/miRNAs-and-lncRNAs-in-melanoma/. The uploaded
network was annotated with additional identifiers for genes, miRNAs, and lncRNAs to
allow quick access to external databases. The vCells platform provides tools to project
data on top of the molecules in the network, e.g. for expression or differential expres-
sion, and to extract sub networks of interest. The network itself is also offered as a
downloadable file.
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